Please assess the completion status of the following clinical trial:

Trial Title: Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Adult stage:~Inclusion criteria:~1. Male or female, age 18 to 50 years~2. Written informed consent, including permission for access to medical records and an HIV test.~3. Available for study follow up and display a willingness and capacity to comply to study procedures.~4. In good general health, as assessed by medical history and a focused physical examination.~5. HIV test (rapid test, ELISA, or PCR) negative~6. Quantiferon®-TB Gold (Cellestis) test for latent TB infection negative within 3 weeks of enrolment~7. BCG vaccination at birth as confirmed by history or the presence of a BCG scar~8. In the case of female participants, a negative urine or serum pregnancy test at enrolment, not lactating, and willingness to use an acceptable method of contraception to avoid pregnancy for the duration of the study~Infant Stage:~Inclusion Criteria:~1. Male or female neonates within 96 hours of birth.~2. Written informed parental consent, including permission to access medical records and results of antenatal HIV tests.~3. Infant participants and their caregivers available for study follow-up and display the willingness and capacity to comply with study procedures.~4. Neonates must be in good general health as assessed by antenatal history, delivery records, and focused physical examination.~5. Birth weight more than or equal to 2500 grams.~6. Apgar score at 5 minutes more than or equal to 7.~7. A maternal HIV test result (rapid test, ELISA or PCR) taken during pregnancy must be available, documented and negative.~8. Estimated gestational age more than or equal to 38 weeks~Exclusion Criteria:~Adult stage Exclusion criteria~1. A history or evidence of an acute or chronic medical or surgical condition likely to affect the safety, reactogenicity, or immunogenicity of the investigational vaccine~2. Skin condition, bruising or birth mark at the intended injection site.~3. History or evidence of previous or current active TB disease~4. History of a household contact with active TB disease who has received less than 2 months treatment~Infant Stage Exclusion criteria:~1. Infant must not have received routine BCG vaccination prior to enrolment.~2. Antenatal, intrapartum, or postnatal medical or surgical condition that may affect the safety, reactogenicity, or immunogenicity of the investigational vaccine.~3. Maternal HIV test (rapid test, ELISA or PCR) not performed antenatally, HIV test results not available, or HIV test result known positive.~4. Maternal or other household contact with newly diagnosed or incompletely treated active TB disease.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- MTBVAC Group 1 (Type: EXPERIMENTAL): Intervention: MTBVAC live vaccine (low dose)
- MTBVAC Group 2 (Type: EXPERIMENTAL): Intervention: MTBVAC live vaccine (middle dose)
- MTBVAC Group 3 (Type: EXPERIMENTAL): Intervention: MTBVAC live vaccine (high dose)
- BCG Control Group (Type: ACTIVE_COMPARATOR): Intervention: commercially available BCG live vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete